Pain & Central Nervous System Week - Jan. 15, 2007
2007 JAN 15 - (NewsRx.com) -- Multiple sclerosis is the most common cause of neurological disability in young adults in the UK. Research and Markets has announced the addition of Espicom Business Intelligence's CNS Drug Discoveries: Multiple Sclerosis Chapter to their offering.
The incidence of multiple sclerosis varies throughout the world, although there is a significantly higher incidence of the disease found in the Northern Hemisphere.
It is variable in presentation and progression. Although there is no cure, there are many symptomatic treatments available. However, many patients do not respond to currently available products (30%) and the more chronic forms (secondary-progressive MS) are poorly treated with existing therapies.
The MS market is estimated to be worth U.S.$4.9 billion in 2006 with a growth rate of 8.9% year-on-year. It is the fifth largest segment of the CNS market and has attracted considerable R&D investment from big pharma, biotechnology companies and specialty pharma.
Sales growth will be driven by current drugs gaining broader indications, MS medicine being prescribed earlier in treatment in clinically-defined multiple sclerosis patients and the longer-term use of combination therapies as more classes of drug become available.
This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2007, Pain & Central Nervous System Week via NewsRx.com.
